Superworth

Neurocrine Biosciences price to book ratio NBIX

Market value divided by the book value of the company's net assets, since 2011.

Today, Nov 2, 2026
4.0×
10-year median
7.3×
Against its 10-year history
3rd
percentile: 0 is its lowest day, 100 its highest
10-year range
3.5× to 29.5×
Peer median
6.3×

Neurocrine Biosciences' price to book ratio is 4.0× as of Nov 2, 2026.

That is below its ten-year median of 7.3×, lower than on 97% of days in the last ten years.

Over that time it ranged from 3.5× in Apr 2025 to 29.5× in Aug 2018.

The median for 10 biotech stocks of a similar size is 6.3×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.0×3.7×5.2×
20254.8×3.5×5.7×
20245.2×4.4×7.0×
20236.5×5.3×7.7×
20227.4×5.3×7.9×
20216.0×5.6×13.6×
202011.1×10.3×18.0×
201917.4×14.5×19.6×
201813.9×13.9×29.5×
201719.8×10.0×19.8×
20169.6×6.9×13.0×
201510.9×6.3×16.1×
20147.7×4.0×10.3×
20134.9×3.9×7.9×
20123.4×3.0×9.9×
20118.1×5.7×16.7×

Against its peers

Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.

CompanyPrice to book ratio
NBIXNeurocrine Biosciences4.0×
HALOHalozyme Therapeutics102×
EXELExelixis9.4×
TECHBIO-TECHNE5.4×
ALNYAlnylam Pharmaceuticals15.7×
RGENRepligen4.6×
INCYIncyte3.8×
KRYSKrystal Biotech6.4×
UTHRUnited Therapeutics4.0×
ONCBeOne Medicines7.8×
ADMAAdma Biologics6.1×
Peer median6.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Neurocrine Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.